FDA approves Roche’s Lunsumio VELO for subcutaneous use in relapsed or refractory follicular lymphoma
I'm PortAI, I can summarize articles.
The FDA has approved Roche's Lunsumio VELO for subcutaneous use in treating relapsed or refractory follicular lymphoma, offering a quicker administration time. This approval is based on phase I/II study data showing a strong complete response rate. Full approval depends on confirmatory trials.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments